The deal
Celaid Therapeutics Inc., a biotechnology startup based in Bunkyo-ku, Tokyo, announced on October 4, 2026 that it has completed the second close of its Series B financing round. The round welcomed Shionogi & Co., Ltd. and Teikoku Ventures, Inc. as new investors, raising ¥400 million (approximately $2.6 million) through a third-party allocation of new shares.
In addition, Celaid passed the second stage-gate review of AMED's "Strengthening Program for Pharmaceutical Startup Ecosystem" and was selected for Stage 3 funding. With this financing and AMED support, the company's cumulative funding to date — including grants — now totals approximately ¥3.42 billion (approximately $22.1 million).
What the company does
Celaid is developing CLD-001, a novel ex vivo-expanded hematopoietic stem cell (HSC) therapy product for severe pediatric non-malignant diseases. Using frozen umbilical cord blood stored in cord blood banks as its cell source, CLD-001 applies the company's proprietary hematopoietic stem cell expansion technology to overcome the limited number of HSCs contained in cord blood, while enabling greater flexibility in selecting cord blood units with more favorable HLA matching.
The target diseases include primary immunodeficiency, inherited metabolic disorders, aplastic anemia, and sickle cell disease — serious conditions where allogeneic HSC transplantation can be curative but faces donor shortages, HLA mismatches, graft failure, transplant-related mortality, and graft-versus-host disease. Cord-blood units are widely banked but historically contain too few stem cells for many patients; Celaid's expansion technology aims to remove that constraint.
The program has hit several concrete milestones: positive nonclinical efficacy and safety data in animal models, an established manufacturing process with technology transfer completed to a U.S. contract development and manufacturing organization (CDMO), and a completed pre-IND meeting with the U.S. Food and Drug Administration. The company is advancing preparations toward an IND submission and the initiation of a first-in-human clinical trial in the United States.
The company originates from the University of Tokyo and the University of Tsukuba, and is pursuing its proprietary HSC expansion platform as a broader business — applying it to new therapeutic modalities and business opportunities in the cell and gene therapy field.
Who's backing it
Shionogi & Co., one of Japan's major pharmaceutical companies, and Teikoku Ventures — the corporate venture capital arm of the Teikoku Seiyaku Group — joined as new investors. Shionogi's head of CVC, Keisuke Kusumoto, said the company believes Celaid's HSC expansion technology represents an innovative approach with the potential to overcome donor shortages and post-transplant complications, and that it aligns with Shionogi's commitment to protecting people's health through new value creation. Teikoku Ventures CEO Mitsuhiro Matsumura said the firm views the technology as a potential foundational platform for cell and gene therapies targeting hematologic malignancies, severe hematologic disorders, and genetic diseases.
Celaid president and CEO Nobuyuki Arakawa said the company is greatly encouraged by the participation of the two new investors and deeply grateful for AMED's advancement to Stage 3, adding that the goal is to become a global leader in the hematopoietic stem cell field and deliver innovative treatment options to patients worldwide from Japan.
Why it matters for founders and investors
A pharma strategic taking a Series B position in a cell therapy startup is a meaningful signal — Shionogi's involvement, alongside AMED's Stage 3 selection, de-risks the story for later investors considering the larger U.S. clinical rounds. The pre-IND meeting completion is the concrete de-risking event here: it means the FDA has weighed in on the path to first-in-human trials.
For founders in biotech, note the financing structure: Celaid has assembled a layered capital stack — venture equity, pharma CVC strategic capital, and substantial non-dilutive AMED grant funding — that has taken cumulative resources past $22 million while keeping the round-by-round equity asks modest. That's a playbook worth studying for any startup in a capital-intensive therapeutic field.
Angeled.com connects founders with investors.
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



